Current Ebola Virus Vaccine Progress

Andrea Marzi, Chad Mire

Research output: Contribution to journalArticle

Abstract

Over 40 years since the discovery of Ebola virus, the anti-Ebola virus vaccine efforts of the past 2 decades have culminated in over 12 different vaccine candidates that have been placed into a number of clinical trial phases, past and present. Of these 12 vaccines, four candidates are up to or in phase II clinical trials, and only one has completed the phase III clinical trial stage. While remarkable progress toward a national regulatory agency-approved vaccine for Ebola virus has been made, there remain unanswered questions on issues such as, but not limited to, vaccine protective immunity and duration of that immunity, and the appropriate vaccination strategy for those at risk of Ebola virus infection.

Original languageEnglish (US)
JournalBioDrugs
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Ebola Vaccines
Vaccines
Immunity
Ebola Hemorrhagic Fever
Ebolavirus
Phase III Clinical Trials
Phase II Clinical Trials
Vaccination
Clinical Trials

ASJC Scopus subject areas

  • Biotechnology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Current Ebola Virus Vaccine Progress. / Marzi, Andrea; Mire, Chad.

In: BioDrugs, 01.01.2019.

Research output: Contribution to journalArticle

@article{10e31652bfe3463ab3a06e76499c4a60,
title = "Current Ebola Virus Vaccine Progress",
abstract = "Over 40 years since the discovery of Ebola virus, the anti-Ebola virus vaccine efforts of the past 2 decades have culminated in over 12 different vaccine candidates that have been placed into a number of clinical trial phases, past and present. Of these 12 vaccines, four candidates are up to or in phase II clinical trials, and only one has completed the phase III clinical trial stage. While remarkable progress toward a national regulatory agency-approved vaccine for Ebola virus has been made, there remain unanswered questions on issues such as, but not limited to, vaccine protective immunity and duration of that immunity, and the appropriate vaccination strategy for those at risk of Ebola virus infection.",
author = "Andrea Marzi and Chad Mire",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s40259-018-0329-7",
language = "English (US)",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Current Ebola Virus Vaccine Progress

AU - Marzi, Andrea

AU - Mire, Chad

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Over 40 years since the discovery of Ebola virus, the anti-Ebola virus vaccine efforts of the past 2 decades have culminated in over 12 different vaccine candidates that have been placed into a number of clinical trial phases, past and present. Of these 12 vaccines, four candidates are up to or in phase II clinical trials, and only one has completed the phase III clinical trial stage. While remarkable progress toward a national regulatory agency-approved vaccine for Ebola virus has been made, there remain unanswered questions on issues such as, but not limited to, vaccine protective immunity and duration of that immunity, and the appropriate vaccination strategy for those at risk of Ebola virus infection.

AB - Over 40 years since the discovery of Ebola virus, the anti-Ebola virus vaccine efforts of the past 2 decades have culminated in over 12 different vaccine candidates that have been placed into a number of clinical trial phases, past and present. Of these 12 vaccines, four candidates are up to or in phase II clinical trials, and only one has completed the phase III clinical trial stage. While remarkable progress toward a national regulatory agency-approved vaccine for Ebola virus has been made, there remain unanswered questions on issues such as, but not limited to, vaccine protective immunity and duration of that immunity, and the appropriate vaccination strategy for those at risk of Ebola virus infection.

UR - http://www.scopus.com/inward/record.url?scp=85059665513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059665513&partnerID=8YFLogxK

U2 - 10.1007/s40259-018-0329-7

DO - 10.1007/s40259-018-0329-7

M3 - Article

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

ER -